A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2019; you can also visit the original URL.
The file type is application/pdf.
Unpicking the Combination Lock for Mutant BRAF and RAS Melanomas
2013
Cancer Discovery
Preserved Fulltext
Large-scale, unbiased combinatorial drug screening has been used to identify effective genotypeselective therapeutic combinations that show promising activity in preclinical models of mutant BRAF and RAS melanoma that are resistant to the clinical BRAF inhibitor vemurafenib. Cancer Discov; 3(1);
doi:10.1158/2159-8290.cd-12-0520
pmid:23319765
fatcat:72rfnitk5vdl7liu3u4epnyls4